| 2024 |
| 07/26 | 1,678 | 1,698 | 1,666 | 1,689 | +1.5% | 6,282,900 | 3兆565億 | +4% |
| 07/25 | 1,660 | 1,670 | 1,642 | 1,664 | +0.24% | 5,379,100 | 3兆112億 | +2.91% |
| 07/24 | 1,650 | 1,672 | 1,645 | 1,660 | +0.36% | 4,592,100 | 3兆40億 | +3.11% |
| 07/23 | 1,642 | 1,657 | 1,639 | 1,654 | +1.04% | 3,627,400 | 2兆9931億 | +3.12% |
| 07/22 | 1,644 | 1,648 | 1,621 | 1,637 | -0.3% | 3,501,400 | 2兆9624億 | +2.44% |
| 07/19 | 1,657 | 1,663 | 1,625 | 1,642 | -3.24% | 9,695,600 | 2兆9714億 | +3.08% |
| 07/18 | 1,687 | 1,704 | 1,678 | 1,697 | +0.53% | 6,558,100 | 3兆709億 | +6.93% |
| 07/17 | 1,667 | 1,698 | 1,666 | 1,688 | +1.99% | 6,754,100 | 3兆547億 | +6.7% |
| 07/16 | 1,656 | 1,660 | 1,644 | 1,655 | -0.12% | 4,617,800 | 2兆9949億 | +4.88% |
| 07/12 | 1,655 | 1,665 | 1,648 | 1,657 | -0.3% | 6,881,900 | 2兆9986億 | +5.21% |
| 07/11 | 1,645 | 1,665 | 1,643 | 1,662 | +1.96% | 7,450,300 | 3兆76億 | +5.73% |
| 07/10 | 1,625 | 1,632 | 1,612 | 1,630 | 0% | 6,399,000 | 2兆9497億 | +3.89% |
| 07/09 | 1,612 | 1,635 | 1,607 | 1,630 | +1.24% | 5,509,000 | 2兆9497億 | +3.95% |
| 07/08 | 1,625 | 1,632 | 1,604 | 1,610 | -0.43% | 8,737,900 | 2兆9135億 | +2.81% |
| 07/05 | 1,615 | 1,623 | 1,605 | 1,617 | +0.81% | 6,136,600 | 2兆9262億 | +3.45% |
| 07/04 | 1,592 | 1,605 | 1,584 | 1,604 | +0.88% | 4,112,200 | 2兆9026億 | +2.75% |
| 07/03 | （5%ルール）アペリオ・グループ・エルエルシー(Aperio Group,…（0.1%）ブラックロック(ネザーランド)BV(BlackRock (Neth…（0.29%）ブラックロック(ルクセンブルグ)エス・エー(Black…（0.09%）ブラックロック・アセット・マネジメント・アイルラ…（0.82%）ブラックロック・アセット・マネジメント・カナダ・…（0.12%）ブラックロック・アドバイザーズ・エルエルシー(B…（0.08%）ブラックロック・インスティテューショナル・トラス…（1.36%）ブラックロック・インベストメント・マネジメント(…（0.12%）ブラックロック・インベストメント・マネジメント(…（0.2%）ブラックロック・インベストメント・マネジメント・…（0.09%）ブラックロック・ジャパン（2.1%）ブラックロック・ファンド・アドバイザーズ(Black…（2.07%）ブラックロック・ファンド・マネジャーズ・リミテッ…（0.31%）ブラックロック・フィナンシャル・マネジメント・イ…（0.06%） |
| 07/03 | 1,585 | 1,595 | 1,583 | 1,590 | +0.13% | 4,632,300 | 2兆8773億 | +2.12% |
| 07/02 | 1,584 | 1,592 | 1,569 | 1,588 | -0.06% | 6,589,400 | 2兆8737億 | +2.12% |
| 07/02 | （IR情報）8:30 前立腺がん治療剤XTANDI中国で適応追加に関する承認を取得 |
| 07/01 | 1,591 | 1,593 | 1,567 | 1,589 | -0.06% | 6,761,000 | 2兆8755億 | +2.25% |
| 06/28 | 1,605 | 1,609 | 1,585 | 1,590 | -0.56% | 8,161,300 | 2兆8773億 | +2.38% |
| 06/27 | 1,578 | 1,614 | 1,566 | 1,599 | +0.95% | 13,702,400 | 2兆8936億 | +2.96% |
| 06/26 | 1,576 | 1,599 | 1,567 | 1,584 | +0.32% | 8,991,800 | 2兆8665億 | +2.13% |
| 06/25 | 1,565 | 1,588 | 1,558 | 1,579 | +1.02% | 5,825,900 | 2兆8574億 | +1.94% |
| 06/24 | 1,542 | 1,567 | 1,537 | 1,563 | +2.16% | 6,467,800 | 2兆8285億 | +1.17% |
| 06/21 | 1,495 | 1,538 | 1,494 | 1,530 | +2.2% | 9,711,900 | 2兆7687億 | -0.84% |
| 06/20 | 1,499 | 1,504 | 1,488 | 1,497 | -0.4% | 3,873,000 | 2兆7090億 | -2.92% |
| 06/19 | 1,501 | 1,509 | 1,494 | 1,503 | -0.13% | 4,073,500 | 2兆7199億 | -2.53% |
| 06/18 | 1,507 | 1,512 | 1,488 | 1,505 | -0.33% | 5,067,000 | 2兆7235億 | -2.46% |
| 06/17 | 1,507 | 1,513 | 1,496 | 1,510 | +0.53% | 4,709,900 | 2兆7325億 | -2.2% |
| 06/14 | 1,483 | 1,510 | 1,482 | 1,502 | -0.33% | 11,925,300 | 2兆7181億 | -2.72% |
| 06/13 | 1,556 | 1,556 | 1,503 | 1,507 | -3.83% | 8,194,700 | 2兆7271億 | -2.46% |
| 06/12 | 1,563 | 1,569 | 1,549 | 1,567 | -0.76% | 4,191,000 | 2兆8357億 | +1.36% |
| 06/11 | 1,590 | 1,597 | 1,574 | 1,579 | +0.13% | 5,214,100 | 2兆8574億 | +2.2% |
| 06/10 | 1,596 | 1,597 | 1,568 | 1,577 | -0.82% | 4,848,900 | 2兆8538億 | +2.07% |
| 06/07 | 1,583 | 1,601 | 1,579 | 1,590 | +0.19% | 5,106,700 | 2兆8773億 | +2.98% |
| 06/06 | 1,595 | 1,603 | 1,583 | 1,587 | -0.5% | 6,315,400 | 2兆8719億 | +2.99% |
| 06/05 | 1,566 | 1,600 | 1,566 | 1,595 | +1.14% | 7,577,200 | 2兆8864億 | +3.64% |
| 06/04 | 1,550 | 1,580 | 1,543 | 1,577 | +1.22% | 6,620,700 | 2兆8538億 | +2.74% |
| 06/03 | 1,563 | 1,570 | 1,545 | 1,558 | +0.58% | 5,259,600 | 2兆8194億 | +1.83% |
| 05/31 | （IR情報）11:30 ゾルベツキシマブFDAが承認再申請を受理 |
| 05/31 | 1,537 | 1,554 | 1,531 | 1,549 | +1.91% | 19,855,300 | 2兆8031億 | +1.44% |
| 05/30 | 1,525 | 1,528 | 1,501 | 1,520 | -1.04% | 7,142,200 | 2兆7506億 | -0.26% |
| 05/29 | 1,555 | 1,558 | 1,526 | 1,536 | -1.73% | 6,325,100 | 2兆7796億 | +0.92% |
| 05/28 | 1,564 | 1,570 | 1,552 | 1,563 | -0.45% | 4,676,000 | 2兆8285億 | +2.83% |
| 05/27 | 1,566 | 1,585 | 1,556 | 1,570 | +0.26% | 6,702,600 | 2兆8411億 | +3.56% |
| 05/24 | 1,546 | 1,572 | 1,543 | 1,566 | +0.32% | 6,817,200 | 2兆8339億 | +3.57% |
| 05/23 | 1,530 | 1,571 | 1,526 | 1,561 | +2.56% | 10,295,300 | 2兆8248億 | +3.51% |
| 05/22 | 1,508 | 1,533 | 1,504 | 1,522 | +1.33% | 5,685,700 | 2兆7543億 | +1.26% |
| 05/21 | 1,503 | 1,510 | 1,497 | 1,502 | -0.66% | 3,960,000 | 2兆7181億 | -0.2% |
| 05/20 | 1,493 | 1,529 | 1,492 | 1,512 | +1.68% | 5,813,700 | 2兆7362億 | +0.27% |
| 05/17 | 1,509 | 1,511 | 1,481 | 1,487 | -1.78% | 8,169,500 | 2兆6909億 | -1.59% |
| 05/16 | 1,525 | 1,530 | 1,510 | 1,514 | -0.72% | 4,790,700 | 2兆7398億 | -0.07% |
| 05/15 | （IR情報）16:00 国内外の当社グループ幹部に対する業績連動型株式報酬制度および業績連動型株式交付制度の継続に関するお知らせ |
| 05/15 | （IR情報）16:00 業績連動型株式報酬制度の継続に関するお知らせ |
| 05/15 | 1,525 | 1,538 | 1,521 | 1,525 | +0.26% | 4,901,000 | 2兆7597億 | +0.39% |
| 05/14 | 1,518 | 1,536 | 1,514 | 1,521 | +0.66% | 6,123,400 | 2兆7524億 | -0.07% |
| 05/13 | 1,519 | 1,523 | 1,501 | 1,511 | -1.11% | 4,597,000 | 2兆7344億 | -0.92% |
| 05/10 | 1,537 | 1,550 | 1,519 | 1,528 | -0.84% | 6,638,000 | 2兆7651億 | -0.07% |
| 05/09 | 1,540 | 1,545 | 1,518 | 1,541 | -0.26% | 5,938,700 | 2兆7886億 | +0.46% |
| 05/08 | 1,556 | 1,568 | 1,545 | 1,545 | -1.15% | 7,330,800 | 2兆7959億 | +0.46% |
| 05/07 | 1,561 | 1,574 | 1,543 | 1,563 | +0.32% | 7,722,200 | 2兆8285億 | +1.36% |
| 05/02 | 1,525 | 1,567 | 1,517 | 1,558 | +2.16% | 8,944,300 | 2兆8194億 | +0.84% |
| 05/01 | 1,514 | 1,536 | 1,510 | 1,525 | +0.73% | 6,920,400 | 2兆7597億 | -1.61% |
| 04/30 | 1,514 | 1,523 | 1,498 | 1,514 | +0.53% | 10,248,700 | 2兆7398億 | -2.7% |
| 04/26 | 1,482 | 1,506 | 1,446 | 1,506 | +3.51% | 13,564,300 | 2兆7253億 | -3.59% |
| 04/25 | （IR情報）15:00 2024年3月期決算説明会資料 |
| 04/25 | （IR情報）15:00 2024年3月期決算補足資料 |
| 04/25 | （IR情報）15:00 2024年3月期決算短信[IFRS](連結) |
| 04/25 | （IR情報）15:00 コアベースの業績の定義変更について |
| 04/25 | （IR情報）15:00 役員の異動について |
| 04/25 | 1,471 | 1,485 | 1,453 | 1,455 | -0.95% | 8,318,300 | 2兆6330億 | -7.21% |
| 04/24 | 1,464 | 1,485 | 1,463 | 1,469 | -1.54% | 10,715,000 | 2兆6583億 | -6.85% |
| 04/24 | （IR情報）8:30 前立腺がん治療剤XTANDI欧州で適応追加に関する承認を取得 |
| 04/23 | 1,478 | 1,506 | 1,478 | 1,492 | +1.08% | 6,786,600 | 2兆7000億 | -5.81% |
| 04/22 | 1,498 | 1,509 | 1,475 | 1,476 | -0.34% | 8,068,600 | 2兆6710億 | -7.17% |
| 04/22 | （IR情報）8:30 過活動膀胱治療剤「Myrbetriq」仮差し止め請求に関する米国デラウェア州連邦地方裁判所の決定について |
| 04/19 | 1,486 | 1,496 | 1,468 | 1,481 | +1.02% | 7,909,200 | 2兆6801億 | -7.21% |
| 04/18 | 1,467 | 1,477 | 1,463 | 1,466 | -0.07% | 6,445,400 | 2兆6529億 | -8.38% |
| 04/17 | 1,455 | 1,489 | 1,448 | 1,467 | +1.03% | 9,854,500 | 2兆6547億 | -8.6% |
| 04/16 | 1,447 | 1,462 | 1,426 | 1,452 | +0.41% | 17,781,200 | 2兆6276億 | -9.81% |
| 04/15 | 1,507 | 1,525 | 1,436 | 1,446 | -7.96% | 30,231,300 | 2兆6167億 | -10.52% |
| 04/12 | （IR情報）16:00 無形資産の減損損失条件付対価に関わる公正価値変動額の計上通期業績予想の修正について |
| 04/12 | 1,577 | 1,585 | 1,569 | 1,571 | -0.88% | 7,614,200 | 2兆8429億 | -3.08% |
| 04/11 | 1,567 | 1,587 | 1,566 | 1,585 | +0.7% | 7,450,600 | 2兆8683億 | -2.28% |
| 04/10 | 1,596 | 1,599 | 1,573 | 1,574 | -1.38% | 6,462,800 | 2兆8484億 | -3.08% |
| 04/09 | 1,591 | 1,603 | 1,591 | 1,596 | -0.06% | 4,866,600 | 2兆8882億 | -1.91% |
| 04/08 | 1,610 | 1,611 | 1,591 | 1,597 | -0.37% | 5,212,600 | 2兆8900億 | -2.02% |
| 04/05 | 1,598 | 1,607 | 1,583 | 1,603 | -0.06% | 8,254,600 | 2兆9008億 | -1.84% |
| 04/04 | 1,629 | 1,631 | 1,603 | 1,604 | -1.05% | 7,907,800 | 2兆9026億 | -1.9% |
| 04/03 | 1,646 | 1,647 | 1,614 | 1,621 | -1.7% | 7,124,300 | 2兆9334億 | -1.04% |
| 04/02 | 1,638 | 1,653 | 1,635 | 1,649 | +0.49% | 6,014,900 | 2兆9841億 | +0.61% |
| 04/01 | 1,652 | 1,671 | 1,641 | 1,641 | -0.18% | 6,093,200 | 2兆9696億 | +0.06% |
| 04/01 | （IR情報）8:30 IZERVAY (avacincaptad pegol) FDAが一部変更承認申請を受理 |
| 03/29 | 1,639 | 1,663 | 1,636 | 1,644 | +1.17% | 8,612,400 | 2兆9750億 | +0.24% |
| 03/28 | （IR情報）13:00 抗体ー薬物複合体エンホルツマブベドチン中国国家薬品監督管理局の医薬品評価センターが生物学的製剤一部変更承認申請を受理 |
| 03/28 | 1,655 | 1,660 | 1,622 | 1,625 | -4.02% | 9,670,000 | 2兆9407億 | -1.04% |
| 03/27 | 1,685 | 1,697 | 1,677 | 1,693 | +1.07% | 12,397,500 | 3兆637億 | +2.98% |
| 03/26 | （IR情報）16:30 「ビロイ点滴静注用100mg」CLDN18.2陽性の治癒切除不能な進行・再発の胃癌の治療薬として日本で製造販売承認取得 |
| 03/26 | 1,650 | 1,680 | 1,642 | 1,675 | +1.27% | 8,019,600 | 3兆311億 | +1.89% |
| 03/25 | 1,676 | 1,676 | 1,654 | 1,654 | -1.08% | 7,191,500 | 2兆9931億 | +0.61% |
| 03/25 | （IR情報）8:30 前立腺がん治療剤XTANDI欧州CHMPが適応追加に関する販売承認勧告を採択 |
| 03/22 | 1,669 | 1,684 | 1,652 | 1,672 | -0.3% | 10,452,200 | 3兆257億 | +1.7% |
| 03/21 | 1,661 | 1,679 | 1,653 | 1,677 | +1.82% | 10,254,800 | 3兆348億 | +2.07% |
| 03/19 | 1,637 | 1,647 | 1,630 | 1,647 | +0.67% | 5,013,800 | 2兆9805億 | +0.24% |
| 03/18 | 1,626 | 1,642 | 1,622 | 1,636 | +1.3% | 6,715,400 | 2兆9606億 | -0.3% |
| 03/15 | 1,600 | 1,616 | 1,596 | 1,615 | +1.38% | 8,037,300 | 2兆9226億 | -1.52% |
| 03/14 | 1,584 | 1,601 | 1,579 | 1,593 | +0.57% | 5,628,000 | 2兆8827億 | -2.93% |
| 03/13 | 1,594 | 1,597 | 1,584 | 1,584 | -0.69% | 7,033,900 | 2兆8665億 | -3.53% |
| 03/12 | 1,611 | 1,611 | 1,573 | 1,595 | -0.19% | 6,782,500 | 2兆8864億 | -3.1% |
| 03/11 | 1,577 | 1,603 | 1,574 | 1,598 | +1.4% | 10,667,900 | 2兆8918億 | -3.15% |
| 03/08 | 1,568 | 1,582 | 1,551 | 1,576 | -1.44% | 18,824,400 | 2兆8520億 | -4.72% |
| 03/07 | 1,625 | 1,631 | 1,596 | 1,599 | -2.32% | 17,418,900 | 2兆8936億 | -3.67% |
| 03/06 | 1,636 | 1,650 | 1,626 | 1,637 | +0.06% | 9,089,400 | 2兆9624億 | -1.62% |
| 03/05 | 1,662 | 1,670 | 1,636 | 1,636 | -2.73% | 11,389,100 | 2兆9606億 | -1.86% |
| 03/04 | 1,686 | 1,687 | 1,663 | 1,682 | +0.42% | 8,117,400 | 3兆438億 | +0.78% |
